Denmark-headquartered Novo Nordisk (NVO) has entered into a collaboration and exclusive worldwide license agreement with ...

Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as ...

Novo Nordisk and Deep Apple ink a deal to develop oral therapies targeting a novel GPCR for cardiometabolic diseases, ...

NVIDIA partners with Novo Nordisk and DCAI to advance drug discovery: Santa Clara, California Thursday, June 12, 2025, 14:00 Hrs [IST] NVIDIA, a world leader in accelerated comput ...

Novo Nordisk has planted another seed to fuel the blossoming of its obesity business, inking an $812 million deal with Deep ...

Nvidia (NASDAQ:NVDA) announced a collaboration with Novo Nordisk (NVO) (OTCPK:NONOF) on Wednesday to speed up the Danish ...

Novo Nordisk ( NVO 6.12%) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky ...

The new multiyear agreement will allow the Danish pharma to use Gefion’s computational power to “process vast datasets” with ...

As part of the license agreement with Novo, Deep Apple will be eligible to receive up to $812 million in payments, as well as ...

Activist hedge fund Parvus Asset Management is building a stake in Ozempic-maker Novo Nordisk as the drugmaker hunts for a ...

For $812 million, Novo Nordisk will enlist Deep Apple to discover and develop a non-incretin therapy for obesity, months ...

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...